UPDATE - AXIM Featured by Reuters: Biotech Receives

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
UPDATE - AXIM Featured by Reuters: Biotech Receives Cannabis Strains at “Discount for Gum to Treat Multiple Sclerosis”

NEW YORK, Jan. 28, 2016 (GLOBE NEWSWIRE) -- A groundbreaking story by Reuters global news agency profiled AXIM ® Biotechnologies, Inc. (OTC:AXIM) and the company’s upcoming clinical trials on the world’s first patented controlled-release cannabinoid chewing gum MedChew Rx™.

The Reuters article documents AXIM’s clinical trials in The Netherlands on MedChew Rx™ to address pain and muscle spasticity in multiple sclerosis (MS) patients – and also compares AXIM ® to UK-based GW Pharmaceuticals’ Sativex ® as well as Botox ®   and baclofen.

Reuters’ statistics in the article emphasize: “There is no cure for multiple sclerosis, or MS, which affects about 400,000 people in the United States. About 80 percent of patients suffer from spasticity, a condition often treated with the muscle relaxant baclofen.” Worldwide, there are about 2.5 million diagnosed with MS .

By the numbers, Reuters points out that Sativex™ costs MS patients on average 5.56 UK pounds, or $8.24 USD per dose, with an estimated use of four doses per day. The U.S. market that MedChew Rx™ is addressing can then be estimated at more than $4.8 billion annually. The article also clarifies, “But state health systems in some countries, including GW's home market, do not consider the drug sufficiently cost-effective to justify coverage.”

Affordable healthcare is a key initiative for AXIM Biotech. The Company has plans to pass on cost savings to patients through MedChew Rx™, which is a patented new cannabinoid-based medicinal delivery method for many indications including pain and spasticity in MS.

Reuters reports that, “The company says it will be able to price its gum cheaper than a major competitor after securing a ‘significant’ discount on cannabis made available by the Dutch government, which has a policy of promoting the drug for medicinal use.”

In addition to the Health Ministry of The Netherlands which is sourcing the pharmaceutical-grade cannabis for AXIM ® Biotech’s product development, the Company has assembled a world-class roster of leading health organizations and professionals. Also supporting the Company’s efforts include:

Bedrocan – The only company in the world producing full bud, standardized medicinal cannabis, Bedrocan is under contract with the Ministry of Health of The Netherlands. Bedrocan provides the base materials for AXIM’s clinical trials.

Professor John Zajicek – The world’s authority on cannabis and neurodegenerative diseases, Prof.  Zajicek is a member of AXIM ® Biotech's advisory board, and also the Chair of Clinical Neuroscience University of St. Andrews U.K., and is entrusted to conduct AXIM’s clinical trials on pain and spasticity in multiple sclerosis.

Syncom BV – A world leader in specialized pharmaceutical chemistry and manufacturing, Syncom BV, is tasked with isolating and purifying the cannabinoid molecules for AXIM’s MedChew Rx™.

QPS – A contract research organization specializing in discovery, pre-clinical and clinical drug development, QPS is entrusted to manage AXIM’s phase 1-3 clinical trials. Leadership at QPS who are involved in AXIM’s MedChew RX development include: Dr. Jan-Bart Hak - Division Director of Clinical Research at QPS, and Dr. Willem J. (Pim) Meijler a Senior Medical Advisor for QPS who is a pain specialist with years of monitoring the effects of cannabis in MS patients. Dr. Meijler will determine proper dosing and efficacy.

Wageningen University – Dr. Renger Witkamp, Prof. of Nutrition and Pharmacology at Wageningen University and a member of AXIM ® Biotech’s Advisory Board, is researching new applications for cannabis on diseases related to inflammation that AXIM is developing MedChew Rx™ for. 

Through these combined efforts, AXIM ® Biotech is set to unveil the world’s next platform for improved and predictable medicine delivery in a convenient piece of chewing gum. It is important to note that MedChew Rx™ has multiple health indication applications outside of pain and spasticity in MS.

“AXIM ® is very proud and excited to have our efforts open up new drug markets and have the Company’s clinical trials on MedChew Rx™ documented by a top global news agency such as Reuters,” states Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM ® Biotech. “The Reuters article correctly documents AXIM’s fast track to a large share of the market and the Company’s place among the very top leaders in the pharmaceutical industry.”

Dr. Anastassov continues, “Although certain similarities in APIs with other available or in developmental stage pharmaceuticals exist, what makes MedChew Rx™ unique and superior is its precise, controlled release mechanism to the oral mucosal capillary circulation, thus bypassing the first-pass, liver metabolism.  Second, it provides neuroprotective and neurostimulatory benefits derived from the act of mastication.”

Professor John Zajicek, a member of AXIM's advisory board, says of cannabis, “Chewing gum is a potentially good route as it would avoid respiratory irritations associated with other delivery methods.  It will deliver a prolonged dose without peaking too much.”

AXIM ® Biotech is focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.) and finding solutions for conditions for which there is currently no effective treatment including: MS , spasticity, pain, Parkinson’s disease, Alzheimer’s disease/ dementia , ADHD (attention deficit hyperactivity disorder), psychosis, PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS, and Crohn’s disease.

Reuters concludes that AXIM ® Biotech, “…hopes its mint-flavored gum will be on sale in the United States as early as 2017. This will depend on whether the Food and Drug Administration grants an accelerated development timeline that would allow it to leapfrog GW, which is waiting to discuss with the agency if and how a late-stage study for Sativex will proceed. AXIM thinks its case could be bolstered by research already undertaken by GW, which has established ‘evidence of safety’ for its drugs derived from natural cannabis.”

Aside from the clinical trials that are ongoing in the EU, AXIM ® Biotech has secured the down payment on land to build the Company’s manufacturing facility in the city of Almere, The Netherlands.  The state-of-the-art, 6,000-square-meter parcel will house a clean laboratory zone, storage areas, offices and technical rooms as well as manufacturing facility equipment. The plans are compliant with the highest European and International standards. AXIM ® Biotech will produce unique pharmaceutical and nutraceutical products – all sourced from hemp.

Research shows that the industrial hemp plant can produce more than 50,000 products. Focusing on innovations in health and the environment, AXIM ® Biotech’s Almere facility will include manufacturing in the following product categories:

  • Functional foods
  • Nutraceuticals
  • Pharmaceuticals
  • Cosmetics
  • Clean energy

AXIM ® Biotech’s manufacturing plans are to leave a net negative carbon footprint in the environment, setting a major global example for “green” innovation and manufacturing.

In addition to coverage from Reuters , AXIM ® Biotech has been featured by media outlets including: Yahoo! Finance , Marketwatch , ABC , NBC , CBS , Telemundo , WGN, Univision, Marijuana Investor News , FOX Business , MainStreet.com , MJ Freeway , Chemical & Engineering News , Dental Tribune , Pharmaceutical Commerce , Dental Products Report and MJI News . For more information, visit AXIM Biotech’s website .

To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 888-829-0070.

About AXIM Biotechnologies: AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy.  For more information, visit the Company website at www.AXIMBiotech.com .

FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.

Contact Info North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 68

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 48

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 164

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 38

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 37

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 71

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

MPE Partners Invests in SKB Cases to Enhance Growth Potential

Updated Category News Views 369

MPE Partners Makes Strategic Investment in SKB Cases MPE Partners, also known as Morgenthaler Private Equity, has announced an exciting investment in SKB Cases, a prominent manufacturer known for its specialty protective cases. With a robust customer base exceeding 2,000 clients across military, industrial, music, and pro AV sectors, this strategic move is set to...

Continue Reading
Aspire Expands into Europe with EU EMI License and Hub Establishment

Updated Category News Views 186

Aspire Expands into Europe with EU EMI License Aspire, a leading global fintech firm based in Singapore, recently announced a significant breakthrough by acquiring its Electronic Money Institution (EMI) license. This important approval lays the groundwork for its operations in the Netherlands, marking the company's formal entry into the European Union. Milestone for...

Continue Reading
GOTS Combats Greenwashing with Consumer Education Campaign

Updated Category News Views 128

GOTS Takes Action Against Greenwashing The Global Organic Textile Standard (GOTS) is excited to announce the return of its #BehindTheSeams campaign, which aims to raise awareness about the sustainable features of GOTS-certified products. This year's campaign will run throughout September, expanding its efforts to educate consumers about the sustainable practices behind...

Continue Reading
Advancements in Cancer Treatment: Insights from Indaptus Therapeutics

Updated Category News Views 123

Exciting Clinical Developments by Indaptus Therapeutics Indaptus Therapeutics, Inc. (Nasdaq: INDP) is making significant strides in the realm of cancer therapy, focusing on innovative treatments for complex conditions such as urothelial cancer. Their ongoing clinical trial, labeled INDP-D101, has revealed promising results regarding their Decoy20 monotherapy. Recently, a...

Continue Reading
Dr. Réjean Boivin Appointed as Editor-in-Chief of Journal

Updated Category News Views 474

Dr. Réjean Boivin Takes the Helm at Review of Scientific Instruments AIP Publishing is excited to welcome Dr. Réjean Boivin as the new editor-in-chief for Review of Scientific Instruments. Boivin, who previously directed the Center of Excellence for Advanced Diagnostics at General Atomics, is a well-respected figure in the field, having held various roles such as...

Continue Reading